β¨ Medicines Approval Notices
16 AUGUST 2007 NEW ZEALAND GAZETTE, No. 91
2395
Product: NovoSeven
Active Ingredient: Factor VIIa, recombinant human 2.4mg
Dosage Form: Powder for injection
Diluent
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Gentofte, Denmark
Indication Change: Single dose treatment
Product: NovoSeven
Active Ingredient: Factor VIIa, recombinant human 4.8mg
Dosage Form: Powder for injection
Diluent
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Gentofte, Denmark
Indication change: Single dose treatment
Product: NovoSeven
Active Ingredient: Factor VIIa, recombinant human 1.2mg
Dosage Form: Powder for injection
Diluent
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Gentofte, Denmark
Indications/Dosage Change:
Dosage regimen for intervention in frequently bleeding patients
Product: NovoSeven
Active Ingredient: Factor VIIa, recombinant human 2.4mg
Dosage Form: Powder for injection
Diluent
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Gentofte, Denmark
Indications/Dosage Change:
Dosage regimen for intervention in frequently bleeding patients
Product: NovoSeven
Active Ingredient: Factor VIIa, recombinant human 4.8mg
Dosage Form: Powder for injection
Diluent
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Gentofte, Denmark
Indications/Dosage Change:
Dosage regimen for intervention in frequently bleeding patients
Dated this 10th day of August 2007.
ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate (pursuant to delegation given by the Minister of Health on 6 July 2001).
go5644
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Exelon Patch 10
Active Ingredient: Rivastigmine 18mg
Dosage Form: Transdermal patch
New Zealand Sponsor: Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer: LTS Lohmann Therapie-Systeme AG, Andernach, Germany
Product: Exelon Patch 15
Active Ingredient: Rivastigmine 27mg
Dosage Form: Transdermal patch
New Zealand Sponsor: Novartis New Zealand Limited Pharmaceutical Sector
Manufacturer: LTS Lohmann Therapie-Systeme AG, Andernach, Germany
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2007, No 91
Gazette.govt.nz —
NZ Gazette 2007, No 91
β¨ LLM interpretation of page content
π₯
Consent to the Distribution of a Changed Medicine
(continued from previous page)
π₯ Health & Social Welfare10 August 2007
Medicines Act 1981, NovoSeven, Factor VIIa, Dosage Change
- ANTHONY HILL, Deputy Director-General, Sector Accountability and Funding Directorate
π₯ Consent to the Distribution of New Medicines
π₯ Health & Social WelfareMedicines Act 1981, Exelon Patch, Rivastigmine, Transdermal patch